Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
In the most recent of three deals announced by Takeda Pharmaceutical Co. Ltd. over three days, LegoChem Biosciences Inc. (LCB) disclosed March 22 that it has entered into a research collaboration and license agreement with the Japanese pharma for the development of antibody-drug conjugates (ADCs) in immuno-oncology